Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Botulinum Toxin Type A for Lateral Canthal Lines
NCT02580370Phase 3Completed
- Sponsor
- Revance Therapeutics
- Start
- Sep 2015
- Primary completion
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of daxibotulinumtoxinA in lateral canthal rhytides, sponsored by Revance Therapeutics. Started Sep 2015; status: completed.
02
Drugs
daxibotulinumtoxinA
03
Conditions
lateral canthal rhytides
Beyond the preview
Go deeper on NCT02580370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02580370.